6 results on '"Kuscu, Cem"'
Search Results
2. Additional file 1: of Recurrent mutations at estrogen receptor binding sites alter chromatin topology and distal gene expression in breast cancer
- Author
-
Jiekun Yang, Xiaolong Wei, Tufan, Turan, Kuscu, Cem, Hayrunnisa Unlu, Farooq, Saadia, Demirtas, Elif, Paschal, Bryce, and Adli, Mazhar
- Subjects
body regions ,skin and connective tissue diseases - Abstract
Figure S1. ERBS shared by more patients contain more mutations after controlling for ER binding intensity. Figure S2. Comparable levels of somatic mutation burden are observed at ERBS overlapping promoter, intronic, and intergenic regions. Figure S3. ERBS are protected from somatic insertions and deletions, and the protective effect is correlated with ER binding intensity. Figure S4. Somatic mutations enriched at ERBS show the APOBEC mutational signature. Figure S5. ERBS with more mutations make more frequent chromatin interactions independent of ER binding intensity. Figure S6. ERBS associated with poor/met outcome contain more somatic mutations. Figure S7. Amplification plots for WT and mutant MCF-7 clones based on the qPCR colony screening strategy depicted in Figure 4d. Figure S8. Somatic mutation reduces ZBTB7A binding. ChIP-qPCR analysis shows ZBTB7A enrichment at the mutation site in MCF-7 WT cells and a mutant clone. Figure S9. High expression of TMEM41B, IPO7 and WEE1 is associated with poor survival for breast cancer patients. Figure S10. Somatic mutation burden at ERBS is higher when blood instead of adjacent to tumor breast tissue is used as â normalâ in the mutation calling process. (PDF 2338 kb)
- Published
- 2018
- Full Text
- View/download PDF
3. Small Molecule Anti-Cancer Compounds Selectively Target the Hemopexin Domain of Matrix Metalloproteinase-9 (MMP-9)
- Author
-
Dufour, Antoine, Sampson, Nicole S., Li, Jian, Kuscu, Cem, Rizzo, Robert C., DeLeon, Jennifer L., Zhi, Jizu, Jaber, Nadia, Liu, Eric, Zucker, Stanley, and Cao, Jian
- Subjects
Models, Molecular ,Binding Sites ,Lung Neoplasms ,Mice, Nude ,Antineoplastic Agents ,Breast Neoplasms ,Cell Growth Processes ,Matrix Metalloproteinase Inhibitors ,Transfection ,Xenograft Model Antitumor Assays ,Article ,Protein Structure, Tertiary ,Substrate Specificity ,Mice ,Matrix Metalloproteinase 9 ,Cell Movement ,Hemopexin ,Cell Line, Tumor ,COS Cells ,Chlorocebus aethiops ,Animals ,Humans ,Protease Inhibitors - Abstract
Lack of target specificity by existing matrix metalloproteinase (MMP) inhibitors has hindered anti-metastatic cancer drug discovery. Inhibitors that bind to non-catalytic sites of MMPs and disrupt protease signaling function have the potential to be more specific and selective. In this work, compounds that target the hemopexin (PEX) domain of MMP-9 were identified using an in silico docking approach and evaluated using biochemical and biological approaches. Two of the selected compounds interfere with MMP-9-mediated cancer cell migration and proliferation in cells expressing exogenous or endogenous MMP-9. Furthermore, these inhibitors do not modulate MMP-9 catalytic activity. The lead compound, N-[4-(difluoromethoxy)phenyl]-2-[(4-oxo-6-propyl-1H-pyrimidin-2-yl)sulfanyl]-acetamide, specifically binds to the PEX domain of MMP-9, but not other MMPs. This interaction between the compound and the PEX domain results in the abrogation of MMP-9 homodimerization and leads to blockage of a downstream signaling pathway required for MMP-9-mediated cell migration. In a tumor xenografic model, this pyrimidinone retarded MDA-MB-435 tumor growth and inhibited lung metastasis. Thus, we have demonstrated for the first time that a novel small molecule interacts specifically with the PEX domain of MMP-9 and inhibits tumor growth and metastasis by reducing cell migration and proliferation.
- Published
- 2011
4. Role of Matrix Metalloproteinase-9 Dimers in Cell Migration: DESIGN OF INHIBITORY PEPTIDES*
- Author
-
Dufour, Antoine, Zucker, Stanley, Sampson, Nicole S., Kuscu, Cem, and Cao, Jian
- Subjects
Models, Molecular ,Protein Conformation ,Blotting, Western ,Transfection ,Cell Movement ,Cell Line, Tumor ,Chlorocebus aethiops ,Animals ,Humans ,Amino Acid Sequence ,Enzyme Inhibitors ,Tissue Inhibitor of Metalloproteinase-1 ,Cell Biology ,Tyrphostins ,Protein Structure, Tertiary ,ErbB Receptors ,Hyaluronan Receptors ,Matrix Metalloproteinase 9 ,COS Cells ,Mutation ,Quinazolines ,RNA Interference ,Protein Multimerization ,Oligopeptides ,Protein Binding ,Signal Transduction - Abstract
Non-proteolytic activities of matrix metalloproteinases (MMPs) have recently been shown to impact cell migration, but the precise mechanism remains to be understood. We previously demonstrated that the hemopexin (PEX) domain of MMP-9 is a prerequisite for enhanced cell migration. Using a biochemical approach, we now report that dimerization of MMP-9 through the PEX domain appears necessary for MMP-9-enhanced cell migration. Following a series of substitution mutations within the MMP-9 PEX domain, blade IV was shown to be critical for homodimerization, whereas blade I was required for heterodimerization with CD44. Blade I and IV mutants showed diminished enhancement of cell migration compared with wild type MMP-9-transfected cells. Peptides mimicking motifs in the outermost strands of the first and fourth blades of the MMP-9 PEX domain were designed. These peptides efficiently blocked MMP-9 dimer formation and inhibited motility of COS-1 cells overexpressing MMP-9, HT-1080, and MDA-MB-435 cells. Using a shRNA approach, CD44 was found to be a critical molecule in MMP-9-mediated cell migration. Furthermore, an axis involving a MMP-9-CD44-EGFR signaling pathway in cell migration was identified using antibody array and specific receptor tyrosine kinase inhibitors. In conclusion, we dissected the mechanism of pro-MMP-9-enhanced cell migration and developed structure-based inhibitory peptides targeting MMP-9-mediated cell migration.
- Published
- 2010
5. Recurrent mutations at estrogen receptor binding sites alter chromatin topology and distal gene expression in breast cancer
- Author
-
Yang, Jiekun, Wei, Xiaolong, Tufan, Turan, Kuscu, Cem, Unlu, Hayrunnisa, Farooq, Saadia, Demirtas, Elif, Paschal, Bryce, and Adli, Mazhar
- Subjects
3. Good health - Abstract
Background: The mutational processes underlying non-coding cancer mutations and their biological significance in tumor evolution are poorly understood. To get better insights into the biological mechanisms of mutational processes in breast cancer, we integrate whole-genome level somatic mutations from breast cancer patients with chromatin states and transcription factor binding events. Results: We discover that a large fraction of non-coding somatic mutations in Estrogen Receptor (ER) positive breast cancers are confined to ER binding sites. Notably, the highly mutated estrogen receptor binding sites are associated with more frequent chromatin loop contacts and the associated distal genes are expressed at higher level. To elucidate the functional significance of these non-coding mutations, we focus on two of the recurrently mutated estrogen receptor binding sites. Our bioinformatics and biochemical analysis suggest loss of DNA-protein interactions due to the recurrent mutations. Through CRISPR interference, we find that the recurrently mutated regulatory element at the LRRC3C-GSDMA locus impacts the expression of multiple distal genes. Using a CRISPR base editor, we show that the recurrent C→T conversion at the ZNF143 locus results in decreased TF binding, increased chromatin loop formation, and increased expression of multiple distal genes. This single point mutation mediates reduced response to estradiol-induced cell proliferation but increased resistance to tamoxifen-induced growth inhibition. Conclusions: Our data suggest that ER binding is associated with localized accumulation of somatic mutations, some of which affect chromatin architecture, distal gene expression and cellular phenotypes in ER positive breast cancer. The dataset represents the source code associated with this work. 
6. Recurrent Mutations At Estrogen Receptor Binding Sites Alter Chromatin Topology And Distal Gene Expression In Breast Cancer
- Author
-
Yang, Jiekun, Wei, Xiaolong, Tufan, Turan, Kuscu, Cem, Unlu, Hayrunnisa, Farooq, Saadia, Demirtas, Elif, Paschal, Bryce, and Adli, Mazhar
- Subjects
3. Good health - Abstract
Background: The mutational processes underlying non-coding cancer mutations and their biological significance in tumor evolution are poorly understood. To get better insights into the biological mechanisms of mutational processes in breast cancer, we integrate whole-genome level somatic mutations from breast cancer patients with chromatin states and transcription factor binding events. Results: We discover that a large fraction of non-coding somatic mutations in Estrogen Receptor (ER) positive breast cancers are confined to ER binding sites. Notably, the highly mutated estrogen receptor binding sites are associated with more frequent chromatin loop contacts and the associated distal genes are expressed at higher level. To elucidate the functional significance of these non-coding mutations, we focus on two of the recurrently mutated estrogen receptor binding sites. Our bioinformatics and biochemical analysis suggest loss of DNA-protein interactions due to the recurrent mutations. Through CRISPR interference, we find that the recurrently mutated regulatory element at the LRRC3C-GSDMA locus impacts the expression of multiple distal genes. Using a CRISPR base editor, we show that the recurrent C→T conversion at the ZNF143 locus results in decreased TF binding, increased chromatin loop formation, and increased expression of multiple distal genes. This single point mutation mediates reduced response to estradiol-induced cell proliferation but increased resistance to tamoxifen-induced growth inhibition. Conclusions: Our data suggest that ER binding is associated with localized accumulation of somatic mutations, some of which affect chromatin architecture, distal gene expression and cellular phenotypes in ER positive breast cancer. The dataset represents the source code associated with this work.
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.